Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Showing 1-25 of 56 citing articles:

The stressed synapse 2.0: pathophysiological mechanisms in stress-related neuropsychiatric disorders
Gerard Sanacora, Zhen Yan, Maurizio Popoli
Nature reviews. Neuroscience (2021) Vol. 23, Iss. 2, pp. 86-103
Closed Access | Times Cited: 126
Hypocretins (orexins): The ultimate translational neuropeptides
Laura H. Jacobson, Daniël Hoyer, Luı́s de Lecea
Journal of Internal Medicine (2022) Vol. 291, Iss. 5, pp. 533-556
Closed Access | Times Cited: 71
New and emerging approaches to treat psychiatric disorders
Katherine W. Scangos, Matthew W. State, Andrew H. Miller, et al.
Nature Medicine (2023) Vol. 29, Iss. 2, pp. 317-333
Closed Access | Times Cited: 70
Accurate Prediction of GPCR Ligand Binding Affinity with Free Energy Perturbation
Francesca Deflorian, Laura Pérez‐Benito, Eelke B. Lenselink, et al.
Journal of Chemical Information and Modeling (2020) Vol. 60, Iss. 11, pp. 5563-5579
Closed Access | Times Cited: 75
Clinical pharmacology, efficacy, and safety of orexin receptor antagonists for the treatment of insomnia disorders
Clemens Muehlan, Cédric Vaillant, Isabelle Zenklusen, et al.
Expert Opinion on Drug Metabolism & Toxicology (2020) Vol. 16, Iss. 11, pp. 1063-1078
Closed Access | Times Cited: 70
The efficacy and safety of dual orexin receptor antagonists in primary insomnia: A systematic review and network meta-analysis
Tao Xue, Xin Wu, Shujun Chen, et al.
Sleep Medicine Reviews (2021) Vol. 61, pp. 101573-101573
Closed Access | Times Cited: 68
Clinical specificity profile for novel rapid acting antidepressant drugs
Mauro Scala, Giuseppe Fanelli, Diana De Ronchi, et al.
International Clinical Psychopharmacology (2023) Vol. 38, Iss. 5, pp. 297-328
Open Access | Times Cited: 26
Targeting Orexin Receptors for the Treatment of Insomnia: From Physiological Mechanisms to Current Clinical Evidence and Recommendations
Maria P. Mogavero, Alessandro Silvani, Giuseppe Lanza, et al.
Nature and Science of Sleep (2023) Vol. Volume 15, pp. 17-38
Open Access | Times Cited: 23
Advances in the Treatment of Chronic Insomnia: A Narrative Review of New Nonpharmacologic and Pharmacologic Therapies
Russell Rosenberg, Leslie Citrome, Christopher L. Drake
Neuropsychiatric Disease and Treatment (2021) Vol. Volume 17, pp. 2549-2566
Open Access | Times Cited: 47
Lateral hypothalamus orexinergic inputs to lateral habenula modulate maladaptation after social defeat stress
Dan Wang, Ao Li, Keyi Dong, et al.
Neurobiology of Stress (2021) Vol. 14, pp. 100298-100298
Open Access | Times Cited: 46
Sleep dysregulation in binge eating disorder and “food addiction”: the orexin (hypocretin) system as a potential neurobiological link
Jacqueline B. Mehr, Deborah Mitchison, Hannah E. Bowrey, et al.
Neuropsychopharmacology (2021) Vol. 46, Iss. 12, pp. 2051-2061
Open Access | Times Cited: 46
Hypocretin/Orexin Receptor Pharmacology and Sleep Phases
Yu Sun, Ryan K. Tisdale, Thomas S. Kilduff
Monographs in clinical neuroscience/Frontiers of neurology and neuroscience/Monographs in neural sciences (2021), pp. 22-37
Open Access | Times Cited: 42
Sleep-wake and arousal dysfunctions in post-traumatic stress disorder: Role of orexin systems
Gary B. Kaplan, Gabrielle A. Lakis, Hryhoriy Zhoba
Brain Research Bulletin (2022) Vol. 186, pp. 106-122
Closed Access | Times Cited: 32
Emerging and upcoming therapies in insomnia
W.-H. Kim, Ho-Sook Kim
Translational and Clinical Pharmacology (2024) Vol. 32, Iss. 1, pp. 1-1
Open Access | Times Cited: 6
The binding mode of vilazodone in the human serotonin transporter elucidated by ligand docking and molecular dynamics simulations
Yang Zhang, Guoxun Zheng, Tingting Fu, et al.
Physical Chemistry Chemical Physics (2020) Vol. 22, Iss. 9, pp. 5132-5144
Closed Access | Times Cited: 41
Efficacy and Safety of Seltorexant as Adjunctive Therapy in Major Depressive Disorder: A Phase 2b, Randomized, Placebo-Controlled, Adaptive Dose-Finding Study
Adam Savitz, Ewa Wajs, Yun Zhang, et al.
The International Journal of Neuropsychopharmacology (2021) Vol. 24, Iss. 12, pp. 965-976
Open Access | Times Cited: 40
Orexin 1 Receptor Antagonism in the Basolateral Amygdala Shifts the Balance From Pro- to Antistress Signaling and Behavior
Jazmine D. W. Yaeger, Kevin T. Krupp, Benjamin Jacobs, et al.
Biological Psychiatry (2022) Vol. 91, Iss. 9, pp. 841-852
Open Access | Times Cited: 22
Orexin Receptor Antagonism: Normalizing Sleep Architecture in Old Age and Disease
J Kron, Ryan J. Keenan, Daniël Hoyer, et al.
The Annual Review of Pharmacology and Toxicology (2023) Vol. 64, Iss. 1, pp. 359-386
Open Access | Times Cited: 15
Targeting orexin receptors: Recent advances in the development of subtype selective or dual ligands for the treatment of neuropsychiatric disorders
Alessandro Bonifazi, Fabio Del Bello, Gianfabio Giorgioni, et al.
Medicinal Research Reviews (2023) Vol. 43, Iss. 5, pp. 1607-1667
Closed Access | Times Cited: 13
Seltorexant for major depressive disorder
K.L. Valentino, Kayla M. Teopiz, Sabrina Wong, et al.
Expert Opinion on Emerging Drugs (2025)
Closed Access
Role of OX/OXR cascade in insomnia and sleep deprivation link Alzheimer’s disease and Parkinson’s disease: Therapeutic avenue of Dual OXR Antagonist (DORA)
Siva Prasad Panda, Suman Sinha, Adarsh Kesharwani, et al.
Biochemical Pharmacology (2025), pp. 116794-116794
Closed Access
Emerging Medications for Treatment-Resistant Depression: A Review with Perspective on Mechanisms and Challenges
Michael J. Lucido, Boadie W. Dunlop
Brain Sciences (2025) Vol. 15, Iss. 2, pp. 161-161
Open Access
Orexin receptors: possible therapeutic targets for psychiatric disorders
Shigeyuki Chaki
Psychopharmacology (2025)
Closed Access
The Insomnia-Addiction Positive Feedback Loop: Role of the Orexin System
Jennifer E. Fragale, Morgan H. James, Jorge A. Avila, et al.
Monographs in clinical neuroscience/Frontiers of neurology and neuroscience/Monographs in neural sciences (2021), pp. 117-127
Open Access | Times Cited: 29
Investigational Drugs for the Treatment of Depression (Part 1): Monoaminergic, Orexinergic, GABA-Ergic, and Anti-Inflammatory Agents
Octavian Vasiliu
Frontiers in Pharmacology (2022) Vol. 13
Open Access | Times Cited: 21
Page 1 - Next Page

Scroll to top